Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | February 18, 2020 | February 19, 2020 |
| Immunovant, Inc.IMVT · Entity 3632 | Director · Chief Executive Officer | October 01, 2026 | October 05, 2026 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | President & Immunovant CEO | September 30, 2026 | October 02, 2026 |
| Sio Gene Therapies Inc.AXGT · Entity 130622 | Director | February 17, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 18, 2020 · Filed February 19, 2020
This filing explicitly reported no securities owned.
Immunovant, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 257,075 |
Ending reported balance
After 2026-10-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 92,187 · Balance 346,467 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Row 2 · 2026-10-01 · Disposition to issuer · Disposed 85,886 · Balance 260,581 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Row 3 · 2026-10-02 · Sale · Disposed 3,506 · Balance 257,075 F3: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Capped Value Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2030-04-01 | Direct | 921,875 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 92,187 · Balance 921,875 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F4: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date.
F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026.
F3: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share.
Roivant Sciences Ltd.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,599,154 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 200,000 · Balance 1,799,154 Row 2 · 2026-09-30 · Sale · Disposed 200,000 · Balance 1,599,154 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2032-04-19 | Direct | 3,644,834 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 200,000 · Balance 3,644,834 F2: Reflects an award of stock options to purchase Common Shares that is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
F2: Reflects an award of stock options to purchase Common Shares that is fully vested.
Sio Gene Therapies Inc.
Report date February 17, 2020 · Filed February 19, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 10, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 299,384 | $9.91 | $2,966,895.44 |
DisclosureSEC source: 0001140361-23-029190 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,097 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| June 09, 2023 Filed Jun 10, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 299,384 | $3.85 | $1,152,628.40 |
DisclosureSEC source: 0001140361-23-029190 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 959,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 201 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-029190 · form4.xml · derivative · entry 5 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,622,568 Underlying: Common Shares · 201 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 201 | $9.85 | $1,979.85 |
DisclosureSEC source: 0001140361-23-029190 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,097 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 201 | $3.85 | $773.85 |
DisclosureSEC source: 0001140361-23-029190 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 415 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-026780 · form4.xml · derivative · entry 4 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,622,769 Underlying: Common Shares · 415 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 15,671 | $9.58 | $150,128.18 |
DisclosureSEC source: 0001140361-23-026780 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,097 F3 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. These sales was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 415 | $9.85 | $4,087.75 |
DisclosureSEC source: 0001140361-23-026780 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,768 F1 · shares: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 415 | $3.85 | $1,597.75 |
DisclosureSEC source: 0001140361-23-026780 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:33 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 238,724 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-024234 · form4.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,623,184 Underlying: Common Shares · 238,724 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:33 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 238,724 | $9.23 | $2,203,422.52 |
DisclosureSEC source: 0001140361-23-024234 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:33 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 238,724 | $3.85 | $919,087.40 |
DisclosureSEC source: 0001140361-23-024234 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2023 Filed May 9, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,206 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-023570 · form4.xml · derivative · entry 6 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,861,908 Underlying: Common Shares · 61,206 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 08, 2023 Filed May 9, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 61,206 | $8.93 | $546,569.58 |
DisclosureSEC source: 0001140361-23-023570 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 08, 2023 Filed May 9, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 61,206 | $3.85 | $235,643.10 |
DisclosureSEC source: 0001140361-23-023570 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 736,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2023 Filed May 9, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 88,838 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-023570 · form4.xml · derivative · entry 5 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,923,114 Underlying: Common Shares · 88,838 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 04, 2023 Filed May 9, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 88,838 | $8.30 | $737,355.40 |
DisclosureSEC source: 0001140361-23-023570 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 04, 2023 Filed May 9, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 88,838 | $3.85 | $342,026.30 |
DisclosureSEC source: 0001140361-23-023570 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 764,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 118,760 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · derivative · entry 9 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,011,952 Underlying: Common Shares · 118,760 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 03, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 118,760 | $8.40 | $997,584.00 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · nonDerivative · entry 6 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 03, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 118,760 | $3.85 | $457,226.00 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · nonDerivative · entry 5 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 794,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 109,074 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · derivative · entry 8 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,130,712 Underlying: Common Shares · 109,074 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 02, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 109,074 | $8.29 | $904,223.46 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 02, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 109,074 | $3.85 | $419,934.90 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 784,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,155 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · derivative · entry 7 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,239,786 Underlying: Common Shares · 61,155 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 61,155 | $8.59 | $525,321.45 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 61,155 | $3.85 | $235,446.75 |
DisclosureSEC source: 0001140361-23-022811 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 736,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,823 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · derivative · entry 9 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,300,941 Underlying: Common Shares · 75,823 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| April 28, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 75,823 | $8.47 | $642,220.81 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · nonDerivative · entry 6 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| April 28, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 75,823 | $3.85 | $291,918.55 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · nonDerivative · entry 5 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 751,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 73,514 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · derivative · entry 8 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,376,764 Underlying: Common Shares · 73,514 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 73,514 | $8.51 | $625,604.14 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| April 27, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 73,514 | $3.85 | $283,028.90 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 749,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 72,906 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · derivative · entry 7 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,450,278 Underlying: Common Shares · 72,906 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 72,906 | $8.66 | $631,365.96 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,768 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| April 26, 2023 Filed Apr 29, 2023 01:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 72,906 | $3.85 | $280,688.10 |
DisclosureSEC source: 0001140361-23-021748 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 748,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 14,457 | $8.80 | $127,221.60 |
DisclosureSEC source: 0001140361-23-019994 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,768 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 23, 2023 Filed Mar 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 14,194 | $7.30 | $103,616.20 |
DisclosureSEC source: 0001140361-23-014076 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,225 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 11,953 | $8.43 | $100,763.79 |
DisclosureSEC source: 0001140361-23-008667 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,419 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 24, 2023 Filed Jan 27, 2023 02:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 13,057 | $8.56 | $111,767.92 |
DisclosureSEC source: 0001140361-23-002961 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,372 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 24,037 | $8.02 | $192,776.74 |
DisclosureSEC source: 0001140361-23-000876 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 95,484 | $7.32 | $698,942.88 |
DisclosureSEC source: 0001140361-23-000545 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. F2 · balance_after: A Form 4 filed by the reporting person on December 28, 2022 inadvertently overstated the total number of Common Shares held by the reporting person by 28,936 Common Shares. The updated amounts reported here correct that error and reflect the reporting person's holdings. Read SEC document |
| December 30, 2022 Filed Jan 5, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 23,761 | $8.00 | $190,088.00 |
DisclosureSEC source: 0001140361-23-000545 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. F2 · balance_after: A Form 4 filed by the reporting person on December 28, 2022 inadvertently overstated the total number of Common Shares held by the reporting person by 28,936 Common Shares. The updated amounts reported here correct that error and reflect the reporting person's holdings. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 02:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 16,031 | $7.10 | $113,820.10 |
DisclosureSEC source: 0001140361-22-047269 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,647 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 09, 2022 Filed Dec 10, 2022 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 133,376 | $7.03 | $937,633.28 |
DisclosureSEC source: 0001140361-22-045162 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,742 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document |
| December 08, 2022 Filed Dec 10, 2022 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 11,729 | $7.00 | $82,103.00 |
DisclosureSEC source: 0001140361-22-045162 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document |
| November 20, 2022 Filed Nov 22, 2022 23:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 16,003 | $5.00 | $80,015.00 |
DisclosureSEC source: 0001140361-22-042829 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,847 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 15,922 | $4.40 | $70,056.80 |
DisclosureSEC source: 0001140361-22-038693 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,850 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 17,392 | $3.07 | $53,393.44 |
DisclosureSEC source: 0001140361-22-034882 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,772 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 16,530 | $3.71 | $61,326.30 |
DisclosureSEC source: 0000899243-22-029892 · doc4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,083,164 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.